Company Overview and News

Hot Chili bags $4 million to advance copper opportunities in Chile

Hot Chili Ltd (ASX:HCH) has successfully closed a placement of shares to sophisticated and institutional investors at 3 cents per share.

Hot Chili secures funds to advance copper project

Hot Chili (ASX:HCH) has successfully closed a $11.3 million private placement with key major shareholders and other sophisticated investors via an offering of unsecured convertible notes.

Hot Chili to provide market update

Hot Chili (ASX:HCH) has been granted a trading halt by the ASX, pending an update concerning exploration activities and financing.

Hot Chili Ltd closes second tranche of $4.4M placement

Hot Chili Ltd (ASX:HCH) has successfully closed the second tranche of a $4.4 million two tranche placement to sophisticated and institutional investors. Following approval from shareholders as per standard procedure, the second tranche of shares priced at $0.05 were issued. Hot Chili is testing a number of large-scale copper porphyry targets at its Productora copper-gold project in Chile. The company is also evaluating a new gold opportunity to the south of Productora, the historical Sierra Zapallo high-grade gold deposit.

Hot Chili, Orinoco raise funds

Local explorers Hot Chili and Orinoco Gold have raised a combined $9 million from investors to fund ongoing work at their respective projects.

Hot Chili Ltd granted ASX halt pending financing update

Hot Chili Ltd (ASX:HCH) has been granted a trading halt by the ASX, pending details about financing. The halt will remain in place until the opening of trade on Friday 24th June 2016, or earlier if an announcement is made to the market.

Change in substantial holding


Closure of $1.6 Million Placement


Appendix 3B


Cleansing Notice


Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...